Epilepsies are common neurological disorders and genetic factors contribute to their pathogenesis. Copy number variations (CNVs) are increasingly recognized as an important etiology of many human diseases including epilepsy. Whole-exome sequencing (WES) is becoming a standard tool for detecting pathogenic mutations and has recently been applied to detecting CNVs.
CNVs, and 2 deletions and 2 duplications at chr15q11.2 of clinically unknown significance. Of note, we were able to identify small CNVs less than 10 kb in size, which might be difficult to detect by conventional microarray. We revealed 2 cases with pathogenic CNVs that one of the 2 CNV detection tools failed to find, suggesting that using different CNV tools is recommended to increase diagnostic yield. Considering a relatively high discovery rate of CNVs (18 out of 168 families, 10.7%) and successful detection of CNV with <10 kb in size, CNV detection by WES may be able to surrogate, or at least complement, conventional microarray analysis.
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| INTRODUCTION
Copy number variations (CNVs) are one of important elements of human genetic diversity and are commonly seen in healthy people. 1 Furthermore, CNVs are recognized as the cause of many human diseases, including neurodevelopmental disorders. 2 Epilepsies are common neurological disorders and genetic factors undoubtedly contribute to their pathogenesis. 2, 3 Microarray technologies play important roles in CNV detection and have acquired higher resolution. Applying microarray analysis to samples from epileptic patients, pathogenic CNVs have been detected in 3.2% to 10.9% of patients in previous reports. [4] [5] [6] [7] [8] [9] Whole-exome sequencing (WES) is a powerful tool for detecting pathogenic mutations, especially single nucleotide variants (SNVs) and small indels, and widely used to find highly heterogeneous genetic alterations. Recently, WES data has been also used for detecting CNVs. [10] [11] [12] [13] [14] Several algorithms for detecting CNVs using WES data have been developed, with varying detection rates. To compensate for the limitations of each algorithm, utilizing different CNV detection tools is recommended for improving results. 13, 14 We performed WES on patients with epilepsy, and conducted WES on 294 families with epilepsy in 2013 to 2014. Among them, we could not find any pathogenic SNVs in 168 families. In this study, we evaluate CNVs in these 168 families using WES data.
| MATERIALS AND METHODS

| Patients
Of the 294 families with epilepsy who underwent WES, 168 families with no pathogenic SNVs in epilepsy-related genes were incorporated to this study ( Figure 1A ). All patients were clinically evaluated and referred to our laboratory seeking research-based diagnosis using 
| Whole-exome sequencing
Peripheral-blood leukocytes or saliva from affected individuals and their families were collected. Genomic DNA was extracted using
QuickGene-610 L (Fujifilm, Tokyo, Japan) or Oragene DNA (DNA Genoteck, Ottawa, Canada) according to the respective manufacturer's protocol. Genomic DNA was sheared and captured using the SureSelect Human All Exon V5 Kit (Agilent Technologies, Santa Clara, California) and sequenced on a HiSeq2500 (Illumina, San Diego, California) with 101-bp paired-end reads. Exome data processing, variant calling, and annotation were performed as previously described. 15 In brief, reads were aligned to GRCh37 with Novoalign (http://www.
novocraft.com/) and polymerase chain reaction (PCR) duplicates were removed using Picard (http://picard.sourceforge.net/). Local realignments around indels and base quality-score recalibration were performed using the Genome Analysis Toolkit (GATK). Variants were called by the GATK UnifiedGenotyper and filtered according to GATK Best Practices (version 3) (https://software.broadinstitute.org/gatk/).
The common variants registered in dbSNP137 (minor allele frequency ≥ 0.01) without known clinical associations were excluded for further analysis. Included variants were annotated using ANNOVAR (http://annovar.openbioinformatics.org/). The WES mean depth of coverage against the RefSeq coding sequence was ×92.0, and 93.1% of the total coding sequence was covered by 10 reads or more.
| CNV analysis
CNVs were examined using WES data with 2 algorithms: the eXomeHidden Markov Model (XHMM), 11 and the program based on relative depth of coverage ratios developed by Nord et al 12 (hereafter referred to as "Nord's method"). Briefly, XHMM detects CNVs based on exome read depth (RD). XHMM uses principal-component analysis (PCA) to normalize raw RD data and the HMM to identify CNVs.
BAM files generated from the Novoalign/Picard/GATK dataprocessing pipeline were used for calculating RD. The mean coverage of the exome-targeted regions of each sample was merged into a samples-by-target matrix. The following downstream analyses were performed using previously described commands 16 In parallel, 303 epilepsy-related genes (Table S1 , Supporting Information) were also checked using Nord's method. These epilepsy-related genes were first selected from The Human Gene Mutation Database professional and Online Mendelian Inheritance in Man using keywords, "epilepsy" or "seizure," and previous reports. Reactions were performed in duplicate. Microarray analysis was performed using CytoScan HD Arrays (Affymetrix, Santa Clara, California) according to the manufacturer's protocol.
| Biological parentage confirmation
In patients with de novo CNVs, we performed haplotype analyses of the families (patients and their parents) using 12 microsatellite markers to confirm biological parentage. The genomic DNA was amplified by PCR with each marker, amplified products were run on ABI 3130xl Genetic Analyzer (Applied Biosystems, Foster City, California), and fragment analyses were carried out using GeneMapper 5 software (Life Technologies, Carlsbad, California).
3 | RESULTS 
| Overview of the studied families
| Detection of rare CNVs using XHMM and Nord's method
In 168 probands with epilepsy, a total of 3797 CNVs were automati- 
| Pathogenic CNVs with epilepsy
We detected 18 pathogenic CNVs in 18 patients (10.7%) as well as recurrent deletions and duplications of unknown clinical significance in 4 patients (2.4%) ( Tables 2 and S2 ). These were all confirmed by qPCR and/or microarray (Figures 2-4) . None of them were previously analyzed by microarray. Six were copy number gains and 12 were deletions. Eight of the 18 pathogenic CNVs were associated with known syndromic epilepsies, and the other 10 contained known epilepsy genes. The known syndromic epilepsy cases included 15q11-q13 interstitial triplication (Case732), 19 Terminal 14q deletion syndrome (Case 741), 20 Pelizaeus-Merzbacher disease (Case 751), 21 Potocki 35 and FOXG1
(Case 995). 36 The size of pathogenic CNVs ranged from 0.26 kb to 45.7 Mb. Nine CNVs were more than 1 Mb in size, and 5 were less than 200 kb (Table 2) . Of note, we were able to detect small intragenic CNVs covering only 1 to 3 exons (Case 842 and Case 952), which are described in section 3.4 ( Figure 4B and C). Ten of the 18 CNVs occurred de novo, 3 were inherited and 5 were unconfirmed because parental samples were unavailable (Table 2) . Five
CNVs were identified in chromosome X (Cases 718, 751, 794, 841, and 931).
In addition, 15q11.2 deletions and duplications were detected in 4 cases (Table S2) . Although recurrent deletions and duplications at 15q11.2 have been reported in 0.25% to 2.1% of patients with epilepsy, the pathogenesis of this region has not been fully elucidated. Abbreviations: CNV, copy number variation; EOEE, early-onset epileptic encephalopathy; WES, whole-exome sequencing.
a Some neonatal onset patients might be included in the infantile onset group due to incomplete clinical information.
b EOEE includes Ohtahara syndrome (n = 2), early myoclonic encephalopathy (n = 2), West syndrome (n = 50), migrating partial seizures of infancy (n = 2), Dravet syndrome (n = 2), and unclassified EOEE (n = 48).
c Other syndromic epilepsy includes Lennox-Gastaut syndrome (n = 5), progressive myoclonus epilepsy (n = 3), and other (n = 7).
d Both chromosomal karyotyping and microarray data were examined in 8 patients.
FIGURE 1
Flowchart of the study and summary of rare CNVs detected by XHMM and Nord's method. A, Flowchart of the study. We performed WES in a total of 294 families and conducted WESbased CNV detection in 168 families after excluding 126 families with causative SNVs (which will be described elsewhere), and found 18 families with pathogenic CNVs. CNVs were detected in 2 ways: (1) 2-step detection: XHMM (detection) and subsequent Nord's method (confirmation) (left in a dotted box), and (2) Nord's method targeting 303 epilepsy genes (right in a dotted box). Seventeen and one pathogenic CNVs were detected by methods (1) and (2) 
| DISCUSSION
In this study, we performed WES CNV analyses on 168 "unsolved"
families with epilepsy and identified pathogenic CNVs in 18 patients (10.7%) ( Table 2 ). Our detection rates of pathogenic CNVs by WESbased CNV analysis are similar to a previous report using microarray (3.2%-10.9%) 4-9 and WES-based (2.9%) 10 analyses in epilepsy. Different diagnostic yields of WES-based CNV detection may arise from It has been shown that XHMM is indeed useful for large CNV detection (>200 kb), and Nord's method specializes in selected/targeted genes. 18, 38, 39 In this study, we showed that these 2 CNV detection tools were able to detect tiny CNVs (0.26 and 1.9 kb) such as a single or 3 exon deletion, as seen in Cases 952 and 842, respectively. The resolution of microarrays depends on the probe density and the target CNV sizes are usually larger than 50 kb. 40 Thus, such small CNVs might be missed by microarray analysis. As shown in Regarding interpreting CNVs, rarer or de novo CNVs are more likely to be pathogenic for human diseases, but we showed in this study that inherited CNVs could also cause the disease. In Case 952, an inherited small deletion involving only 1 exon within a gene reported in a healthy cohort (frequencies 0.0000574-0.00345 reported in DGV) can be 1 hit in the autosomal recessive condition ( Figure 4C ). Therefore, we should carefully evaluate CNVs found in controls together with SNVs in coding regions.
CNVs are important causes of human diseases including epilepsy.
In Case 738, the patient was suspected to have GLUT1 deficiency syndrome from their clinical findings, but SLC2A1 sequencing revealed no causative mutation. Through WES analysis, no SNVs in epilepsy-associated genes, including SLC2A1, were identified, but
CNVs involving the entire SLC2A1 were found, leading to the genetic diagnosis of GLUT1 deficiency syndrome ( Figure 3A ).
To date, genetic workup for epilepsies is recommended to start with microarray analysis, then move on to sequencing for a few genes and/or targeted panels, and finally perform WES in remaining undiagnosed cases. 10, 41 However, an "exome-first approach," WES for evaluating both SNVs and CNVs, could be an alternative to avoid a "diagnostic odyssey," as in our Case 738, and may save time and cost. 18, 42 It has been reported that SNVs and CNVs involving epilepsy genes account for 10.0% to 48.5% 41 and 3.2% to 10.9% 4-9 of genetic causes, respectively. In our study using WES, pathogenic SNVs were identified in 126 (42.9%) and CNVs in 18 (6.1%) out of 294 families ( Figure 1A ), being compatible with these previous data. Therefore, it would be acceptable to investigate pathogenic SNVs first and then
CNVs only by WES. Moreover, numerous candidate genes, with new genes continually being identified, make a Sanger sequencing approach unrealistic. 43 Even frequent updates of gene panels are proving difficult to manage. Therefore WES could be a first-tier test, considering its high diagnostic yields in epilepsy.
In conclusion, we identified pathogenic CNVs using WES data in 
